Etomidate in electroconvulsive therapy. A within-patient comparison with alphaxalone/alphadalone.
In a group of 31 patients undergoing electroconvulsive therapy, there was no significant difference between the times of return of eyelash reflex, swallowing and respiration following a single induction dose of 0.2 mg/kg of etomidate as compared with an induction dose of 0.036 ml/kg of alphaxalone/alphadalone. The incidence of involuntary movements and increased muscle tone was significantly greater after etomidate than following alphaxalone/alphadalone; but the involuntary movements were never marked. The overall incidence of pain on injection was 15% after etomidate. There was a low incidence of venous sequelae following either drug.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000530:Alfaxalone Alfadolone Mixture / Q000009:adverse effects; D000771:Anesthesia, Intravenous / Q000009:adverse effects; D004565:Electroconvulsive Therapy; D005045:Etomidate / Q000009:adverse effects; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011277:Pregnanediones / Q000009:adverse effects
D007093:Imidazoles; D011277:Pregnanediones; D000530:Alfaxalone Alfadolone Mixture; D005045:Etomidate